Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Ocular Therapeutix (OCUL) over the last 11 years, with Q3 2025 value amounting to $183.9 million.

  • Ocular Therapeutix's Shares Outstanding (Weighted Average) rose 1013.64% to $183.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.9 million, marking a year-over-year increase of 1013.64%. This contributed to the annual value of $60.8 million for FY2020, which is 3419.02% up from last year.
  • Ocular Therapeutix's Shares Outstanding (Weighted Average) amounted to $183.9 million in Q3 2025, which was up 1013.64% from $172.6 million recorded in Q2 2025.
  • Ocular Therapeutix's Shares Outstanding (Weighted Average)'s 5-year high stood at $183.9 million during Q3 2025, with a 5-year trough of $77.4 million in Q1 2023.
  • For the 3-year period, Ocular Therapeutix's Shares Outstanding (Weighted Average) averaged around $143.3 million, with its median value being $166.4 million (2024).
  • As far as peak fluctuations go, Ocular Therapeutix's Shares Outstanding (Weighted Average) surged by 11246.59% in 2024, and later surged by 408.26% in 2025.
  • Ocular Therapeutix's Shares Outstanding (Weighted Average) (Quarter) stood at $78.0 million in 2023, then surged by 113.96% to $167.0 million in 2024, then grew by 10.14% to $183.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $183.9 million for Q3 2025, versus $172.6 million for Q2 2025 and $169.4 million for Q1 2025.